东北制药2025年前三季度研发费用1.04亿元，同比增长95%

Core Viewpoint - Northeast Pharmaceutical is significantly increasing its R&D investment, with R&D expenses reaching 104 million yuan in the first three quarters of 2025, a year-on-year increase of 95%, focusing on innovative drug pipelines such as cell therapy [1] R&D Investment - The company’s R&D expenses for the first three quarters of 2025 amounted to 104 million yuan, reflecting a 95% year-on-year growth [1] - Key investments are directed towards innovative drug pipelines, particularly in cell therapy [1] Clinical Trials and Product Development - The company’s subsidiary, Beijing Dingcheng Peptide Source, has received approval for clinical trials of DCTY0801 injection and has obtained orphan drug designation from the FDA [1] - DCTY1102 injection, a TCR-T drug, is the first targeted KRAS G12D product to enter Phase I clinical trials in China, showcasing the company's technological breakthroughs in biopharmaceuticals [1] Financial Performance - After the mixed-ownership reform, the operational efficiency of Northeast Pharmaceutical has improved, with a projected net profit attributable to shareholders of 410 million yuan for 2024, representing a year-on-year increase of 14.34% [1] - In the first three quarters of 2025, the company's non-recurring net profit increased by 27.54% year-on-year, indicating strong profitability resilience and successful innovation transformation [1] Quality Assurance and Market Trust - The company’s raw material drug manufacturing facility passed audits from seven domestic and international clients in mid-February, covering five core products including Vitamin C, achieving a 100% pass rate [1] - This success further consolidates the company's trust in the international market [1] Stock Performance - Recently, Northeast Pharmaceutical's stock has shown volatility, closing at 5.20 yuan on February 26, 2026, with a daily decline of 0.38% and a cumulative increase of 1.36% over the last three trading days [1] - On February 26, the main capital inflow was 7.87 million yuan, while retail investors showed a net outflow [1] - Technically, the stock price is positioned between a resistance level of 5.5 yuan and a support level of 5.06 yuan, with a weak MACD indicator, indicating a need to monitor breakout situations in the short term [1]